General interest

For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.

The European Academy of Neurology is looking for an Editor-in-Chief for their future e-Learning platform.

Alzheimer Europe calls for urgent action to address the impact of COVID-19 on dementia research

External interview: Prof. Muresanu, Chair of the EAN Communication Committee interviews Prof. Thomas Berger

EAN signed a Memorandum of Understanding with EANS – European Association of Neurosurgical Societies joining forces to promote optimal cooperation in Europe between both societies.

Executive Page: Thomas Berger, Chair of the Scientific Committee

For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.

Country of the month: Moldova

New officers of the Board were elected by institutional and individual on 10th June 2020 via post due to restrictions imposed by COVID-19.

This Guideline addresses a number of medical issues which neurologists and other medical doctors who are involved in the medical management of patients with dementia are confronted with on a regular basis.

In this study recently published in Brain, the authors collected detailed clinical and paraclinical data from patients with suspected COVID-19-related neurological disorders in whom the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organisation criteria.

In this research letter recently published in JAMA, the authors assessed persistent symptoms in patients who had been discharged from hospital after recovery from COVID-19.

Anosmia, stroke, paralysis, cranial nerve deficits, encephalopathy, delirium, meningitis, and seizures are some of the neurological complications in patients with COVID-19.

In this study, recently published in Brain, the authors present cerebrovascular disease case incidence in hospitalised patients with SARS-CoV-2 infection.

In this paper, the authors retrospectively reviewed all COVID-19–positive patients admitted to the neuroscience intensive care unit for monitoring of malignant cerebral oedema